Valens GroWorks Corp. (CSE:VGW) (the “Company” or “Valens”), is pleased to announce the signing of a Memorandum of Understanding (“MOU“) with the Bill Nelems Pain and Research Centre, operating the Okanagan Interventional Pain Clinic, to form a strategic alliance for the purpose of conducting clinical research and development of safe, efficacious and reliable pharmaceutical-grade medicinal cannabis products (CBD and THC combinations) specific for the treatment of particular conditions.

The Bill Nelems Pain and Research Centre (“BNPRC“) serves as the main referral pain centre for approximately 750,000 patients within the Interior Health region, as well as patients from the Northern Health region in British Columbia. This centre specializes in comprehensive pain care, including cutting-edge interventional options, and interdisciplinary pain management.
Tyler Robson, CEO of Valens stated, “It is a great honour to forge this alliance with BNPRC, and an opportunity to realize our vision as a high-science company at the forefront of the cannabis sector, and our objective towards becoming a leading purveyor of cannabis products and technologies.” Robson adds, “The collaboration of our scientists with front-line physicians fast-tracks the development of effective and reliable pharmaceutical-grade medicinal cannabis products to best serve prescribing physicians and their patients. The resulting formulations will platform an industry-leading Valens RX™ line of products with proven efficacy that doctors, and their patients, can rely on.”
Dr. Paul Etheridge, the Medical Director at the BNPRC commented, “Our doctors have been prescribing medicinal marijuana as an alternative to pharmaceutical drugs such as opioids for the treatment of various conditions, including the reduction of chronic pain and PTSD.” He continued, “It is however challenging to determine the effective combination of CBD and THC and other cannabinoids for treatment of patients and particular conditions. This collaboration provides us access to Valens’ high-level analytical testing capabilities and licensed capability to develop customized medicinal formulations from Cannabis plants.”
Dr, Rob O’Brien, President of Valens AgriTech Ltd and Chief Scientific Officer at Supra THC Services, Valens’ Health Canada licenced wholly-owned subsidiaries, added, “In order for Cannabis based products to be acceptable as medicines, physicians need to understand the complex relationship between a prescribed dose and how the Cannabis cannabinoids interact with the patient’s system. Our Center of Excellence in “Plant Based Medicine Analytics” possesses the advanced instrumentation and scientific expertise needed to measure cannabinoid metabolites as well as the patient’s biomarkers. This strategic alliance with front-line physicians will lead to an increased understanding of how Cannabis products interact with the human system and may provide physicians with a natural and effective alternative to opioids and other potentially harmful pharmaceuticals when treating chronic pain and related conditions.”
About Valens GroWorks Corp.
Valens GroWorks Corp. is a CSE-listed biotechnology company with an aggressive buildout strategy. The Company seeks to capture a broad spectrum of medical cannabis users, and adult recreational users once legalized, as well as clinical trial and R&D clients, in pursuit of its ambitious “plants to premium products” objectives. The Company also provides management, consulting, testing and support services to domestic and international clients.
The Company operates a 17,000 square foot facility located on two acres in Kelowna, in the heart of British Columbia’s Okanagan Valley. Wholly owned subsidiary Supra THC Services Inc. (“Supra“) recently announced a collaboration with Thermo Fisher Scientific, a world leader in Health Science services, to develop a “Centre of Excellence in Plant Based Medicine Analytics” to provide analytical services and directed research and development, including clinical trials. Supra, and the Company’s wholly owned subsidiary Valens AgriTech Ltd. (“Valens AgriTech“), a Health Canada Licensed Dealer, recently announced a $330,000 MITACS funded research grant to support a collaboration with UBC Okanagan and Thompson Rivers University to explore potential cannabis bio-products including pharmaceuticals, nutritional products, and industrial fiber.
On behalf of the Board of Directors,
(signed) “Tyler Robson
Chief Executive Officer
Notice regarding Forward Looking Statements
This news release contains certain “forward-looking statements” within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Corporation is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
The CSE or other regulatory authority has not reviewed, approved or disapproved the contents of this press release. We seek Safe Harbour.
Click here to connect with Valens GroWorks Corp. (CSE:VGW) for an Investor Presentation


Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development

Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.

Keep reading... Show less

The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.

With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.

Keep reading... Show less

HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.

DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.

Keep reading... Show less

CFN Enterprises Inc. (OTCQB: CNFN) (CFN Media) partners with FMW Media Works LLC to produce a regular series on the global cannabis markets to air on major financial news networks across the US. Initial segment features leading cannabis analyst and US Multi-State Operator (MSO)

CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announced that its inaugural news segment on the cannabis markets, “Cannabis Market Outlook for 2021,” will air on Bloomberg, Newsmax and Fox Business.

Keep reading... Show less